Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Martin Kolb, Bruno Crestani, Toby M. Maher
European Respiratory Review (2023) Vol. 32, Iss. 167, pp. 220206-220206
Open Access | Times Cited: 39

Showing 1-25 of 39 citing articles:

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Francesco Bonella, Paolo Spagnolo, C.J. Ryerson
Drugs (2023) Vol. 83, Iss. 17, pp. 1581-1593
Open Access | Times Cited: 52
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Rebecca C. Keith, Anoop M. Nambiar
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access | Times Cited: 2
Exploring the Therapeutic Landscape: A Narrative Review on Topical and Oral Phosphodiesterase-4 Inhibitors in Dermatology
Elena Carmona‐Rocha, Lluís Rusiñol, L. Puig
Pharmaceutics (2025) Vol. 17, Iss. 1, pp. 91-91
Open Access | Times Cited: 1
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)
Luca Richeldi, Arata Azuma, Vincent Cottin, et al.
BMJ Open Respiratory Research (2023) Vol. 10, Iss. 1, pp. e001563-e001563
Open Access | Times Cited: 18
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions
Vasiliki Liakouli, Antonio Ciancio, Francesco Del Galdo, et al.
Nature Reviews Rheumatology (2023) Vol. 20, Iss. 1, pp. 21-32
Closed Access | Times Cited: 18
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review
Andrew Blauvelt, Richard Langley, Kenneth B. Gordon, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 12, pp. 3031-3042
Open Access | Times Cited: 17
Highlights on Future Treatments of IPF: Clues and Pitfalls
Alessandro Libra, Enrico Sciacca, Giuseppe Muscato, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8392-8392
Open Access | Times Cited: 8
Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis
Zezhou Shi, Min Zhou, Jingfang Zhai, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 5
Evidence from recent clinical trials in fibrotic interstitial lung diseases
Vincent Cottin, Claudia Valenzuela
Current Opinion in Pulmonary Medicine (2024) Vol. 30, Iss. 5, pp. 484-493
Closed Access | Times Cited: 5
PDE4B inhibition by nerandomilast: Effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells
Dennis Reininger, Katrin Fundel‐Clemens, Christoph H. Mayr, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 23, pp. 4766-4781
Open Access | Times Cited: 5
Structural insights into the lead identification of sub-type selective PDE4B inhibitors from plant bioactive molecule analogues
Bhanu Sharma, Rituraj Purohit
Journal of Molecular Liquids (2023) Vol. 390, pp. 123039-123039
Closed Access | Times Cited: 13
Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease
Kunrong Yu, Wanying Li, Wenjie Long, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation- A case report
Stefanie Klampfleitner, Andreas Fertl, Ositha Prinz, et al.
Respiratory Medicine Case Reports (2025), pp. 102168-102168
Open Access
Distinct cAMP regulation in scleroderma lung and skin myofibroblasts governs their dedifferentiation via p38α inhibition
J.D. Baas, John Varga, Carol Feghali‐Bostwick, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Nanodrug Delivery System for Precision Treatment of Pulmonary Fibrosis
Xianhao Yi, Xinru Zhang, Y. Guan, et al.
Precision medicine and engineering. (2025), pp. 100025-100025
Open Access
Advances and future outlook in clinical trials for treating systemic sclerosis-interstitial lung disease
Marzieh Jamali, R Vázquez‐Sánchez, Prachi Agarwal, et al.
Expert Review of Respiratory Medicine (2025)
Closed Access
Idiopathic Pulmonary Fibrosis, Today and Tomorrow: Certainties and New Therapeutic Horizons
G. Giulianelli, Elisabetta Cocconcelli, Giordano Fiorentù, et al.
Pulmonary Therapy (2025)
Open Access
Ensifentrine: a novel approach to redefining COPD management and implications for additional respiratory diseases
Frank C. Sciurba, Shijing Jia, Shyam Subramanian
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis
Yue Li, Congshan Jiang, Wenhua Zhu, et al.
Science Progress (2024) Vol. 107, Iss. 2
Open Access | Times Cited: 3
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease
Dinesh Khanna, Luke Evnin, Shervin Assassi, et al.
Journal of Scleroderma and Related Disorders (2024)
Open Access | Times Cited: 3
Phosphodiesterase 4 is overexpressed in human keloids and its inhibition reduces fibroblast activation and skin fibrosis
Javier Milara, Pilar Ribera, Severiano Marín, et al.
Chemico-Biological Interactions (2024) Vol. 402, pp. 111211-111211
Open Access | Times Cited: 2
Nerandomilast Improves Bleomycin-Induced Systemic Sclerosis-Associated Interstitial Lung Disease in Mice by Regulating the TGF-β1 Pathway
Yuming Liu, Zhigang Liu, Xiaohe Li, et al.
Inflammation (2024)
Closed Access | Times Cited: 2
A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection
Afsal Kolloli, Santhamani Ramasamy, Ranjeet Kumar, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis
Basavaraj Vastrad, Chanabasayya Vastrad
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Neutrophil and Endothelial Cell Membranes Coassembled Roflumilast Nanoparticles Attenuate Myocardial Ischemia/Reperfusion Injury
Ying Tan, Xun Wang, Yu Gu, et al.
Nanomedicine (2024) Vol. 19, Iss. 9, pp. 779-797
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top